Conatus Pharmaceuticals (NASDAQ:CNAT) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Thursday.
A number of other brokerages also recently commented on CNAT. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 4th. Oppenheimer set a $14.00 target price on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $11.80.
CNAT stock traded up $0.13 during trading on Thursday, reaching $4.28. 530,600 shares of the stock were exchanged, compared to its average volume of 602,100. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.35 and a quick ratio of 2.35. Conatus Pharmaceuticals has a 1 year low of $3.22 and a 1 year high of $7.95. The company has a market capitalization of $122.39 million, a PE ratio of -7.02 and a beta of 1.38.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its earnings results on Friday, August 3rd. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.05. Conatus Pharmaceuticals had a negative net margin of 48.46% and a negative return on equity of 69.68%. The company had revenue of $8.77 million for the quarter, compared to the consensus estimate of $9.06 million. Sell-side analysts forecast that Conatus Pharmaceuticals will post -0.66 EPS for the current year.
A number of hedge funds have recently modified their holdings of CNAT. BlackRock Inc. increased its position in shares of Conatus Pharmaceuticals by 45.4% during the first quarter. BlackRock Inc. now owns 2,316,808 shares of the biotechnology company’s stock valued at $13,601,000 after acquiring an additional 723,413 shares during the last quarter. Alambic Investment Management L.P. increased its position in shares of Conatus Pharmaceuticals by 207.0% during the second quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock valued at $1,133,000 after acquiring an additional 178,461 shares during the last quarter. Bank of America Corp DE increased its position in shares of Conatus Pharmaceuticals by 75.7% during the second quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock valued at $602,000 after acquiring an additional 60,604 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of Conatus Pharmaceuticals during the second quarter valued at about $547,000. Finally, JPMorgan Chase & Co. increased its position in shares of Conatus Pharmaceuticals by 1,205.7% during the first quarter. JPMorgan Chase & Co. now owns 74,062 shares of the biotechnology company’s stock valued at $435,000 after acquiring an additional 68,390 shares during the last quarter. 33.49% of the stock is currently owned by institutional investors.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Featured Story: How to Track your Portfolio in Google Finance
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.